Can p63 serve as a biomarker for diagnosing giant cell tumor of bone? A systematic review and meta-analysis.

Tumor protein p63 (p63) has been reported to be highly expressed in giant cell tumor of bone (GCTB). Whether p63 can be treated as a diagnostic marker for GCTB remains unclear. We conducted a meta-analysis to evaluate the applicability of p63 in diagnosing GCTB. Systematic review and meta-analysis carried out in a public hospital, Hong Kong, China. We searched PubMed, EMBASE and the Cochrane Library from inception to April 30, 2019. Literature in English or Chinese about the differential diagnosis of GCTB using p63 were included. -Animal experiments, reviews, correspondence, case reports, expert opinions and editorials were excluded. Studies were also excluded if they did not provide sufficient information to construct a 2 × 2 contingency table. We calculated individual and pooled sensitivities and specificities. We used I² as an indicator of heterogeneity. Out of 88 records identified, 8 articles on 788 GCTB patients fulfilled the inclusion criteria and were included in the present analysis. Bivariate analyses yielded a pooled mean sensitivity of 0.87 (95% confidence interval, CI, 0.72-0.95) and specificity of 0.71 (95% CI, 0.56-0.82) for using p63 as a biomarker in diagnosing GCTB. The area under the receiver operating characteristic curve was 0.86 (95% CI, 0.82-0.88). p63 is a helpful indicator in diagnosing GCTB due to its high sensitivity and specificity. -Nonetheless, the results need to be carefully interpreted based on other diagnostic methods such as imaging. 164115 (PROSPERO registration number).

Citation

Zihao Wan, Chien-Wei Lee, Shuai Yuan, Oscar Kuang-Shen Lee. Can p63 serve as a biomarker for diagnosing giant cell tumor of bone? A systematic review and meta-analysis. Sao Paulo medical journal = Revista paulista de medicina. 2020 Oct 20;138(5):393-399

Mesh Tags

Substances

PMID: 33111920

search → result